Literature DB >> 22527475

Acute myocardial infarction and subacute stent thrombosis associated with cabazitaxel: a case report.

Seher Gokay1, Davran Cicek, Haldun Muderrisoglu.   

Abstract

CASE: Although newer cancer treatments and supportive care treatments have led to vast improvements in the management of complications associated with cancer treatment, sometimes they might cause serious side effects such as coronary artery disease, myocardial infarction and heart failure. These complications may occur any time during or after chemotherapeutics. In this report we present a patient with prostate cancer who experienced myocardial infarction and stent thrombosis probably caused by cabazitaxel -a new chemotherapeutic agent- administration.
CONCLUSION: Cardiologists and oncologists should take into consideration the cardiac side effects of new chemotherapeutic agents with the aim of maximizing both quality of life and survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527475     DOI: 10.1007/s11096-012-9629-z

Source DB:  PubMed          Journal:  Int J Clin Pharm


  16 in total

Review 1.  Cardiovascular effects of systemic cancer treatment.

Authors:  Elżbieta Senkus; Jacek Jassem
Journal:  Cancer Treat Rev       Date:  2010-12-03       Impact factor: 12.111

2.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 3.  Anticancer therapy induced cardiotoxicity: review of the literature.

Authors:  Sandra Geiger; Veronika Lange; Patricia Suhl; Volker Heinemann; Hans-Joachim Stemmler
Journal:  Anticancer Drugs       Date:  2010-07       Impact factor: 2.248

Review 4.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

5.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

6.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 8.  [Cardiac toxicity in cancer therapy].

Authors:  Aleksandra Łacko; Iwona Włodarska; Robert Zymliński; Grzegorz Mazur; Tomasz Wróbel; Iwona Gisterek
Journal:  Pol Merkur Lekarski       Date:  2002-07

9.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

Review 10.  Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.

Authors:  Channing J Paller; Emmanuel S Antonarakis
Journal:  Drug Des Devel Ther       Date:  2011-03-10       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.